Session Chair Profile

M.D., Associate Professor in the Department of Neurosurgery, Duke University Medical Center

Dr. Gromeier has re-engineered poliovirus for safe use as a cancer immunotherapy vehicle. The re-engineered virus, called PVSRIPO, cannot replicate in the normal brain, but can effectively target and destroy virtually all (solid tumor) neoplastic cells, due to ectopic expression of the poliovirus receptor CD155 on such cells. Tumor cell killing is not the principal means of efficacy, but sets up a range of pro-inflammatory and immunogenic events that can engender lasting anti-tumor immune effector responses. Phase I trials in recurrent glioblastoma (GBM) have produced durable complete clinical and radiographic responses in some patients.


Cancer Immunotherapy with Oncolytic Poliovirus

Oncolytic poliovirus immunotherapy is showing promise in patients with recurrent glioblastoma, a particularly challenging indication in oncology, that is resistant to all available modalities. Dr. Gromeier will discuss mechanisms of viral oncolytic immunotherapy and outline a path towards effective clinical application.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).